RoosterBio and MBL Beijing Biotech team up to accelerate advanced therapy manufacturing in China

By Rachel Arthur

- Last updated on GMT


Related tags Exosomes bioreactors China upstream downstream

RoosterBio has entered into an exclusive distributor partnership with MBL Beijing Biotech: with RoosterBio’s expansion media, exosome collection media, bioreactor media and genetic engineering media to be sold and distributed by MBL Beijing and thus becoming readily accessible for the first time to MSC and exosome therapy developers in China.

RoosterBio, a Maryland, US, supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services, says the partnership ties in with its aims to expand globally this year and beyond.

“RoosterBio’s engineered media products are creating transformative impact for cell and exosome therapy developers all over the world,”​ said Tim Kelly, CEO. “One of our key objectives in 2022 is to expand global access to our best-in-class products and services, particularly in Europe and Asia. Some of the most exciting R&D in the MSC and exosome space is being conducted in China, so we have sought to partner with an industry leader in that region.”

In addition to product distribution, the agreement creates an access path to RoosterBio’s process development and analytical services, which help advanced therapy developers move candidates into the clinic. These services, combined with media solutions, 'offers therapy developers a complete solution, addressing upstream expansion of hMSC’s in 2D flasks or 3D bioreactors, optimized conditions for exosome collection, and downstream processes to achieve purity, yield, and potency of the final formulated drug product.'

Tamao Kaku, Managing Director of MBL Beijing (a JSR Life Sciences company supplying  products to support life sciences), said: “After evaluating the current solutions available, we determined that drug developers in China will greatly benefit from the RoosterBio technology platform and product portfolio. We are pleased to have the opportunity to support our cell and exosome therapy developers by offering this industry-leading solution.”

MBL Beijing will start accepting and fulfilling RoosterBio orders in September 2022.

Related news

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more